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Abstract 109 
Objective:  To determine the influence of Roux-en-Y gastric bypass (RYGB) on medication-110 
related costs.  111 
Methods: Analysis of types, dosages and costs of drugs and medical devices prescribed 112 
before and after surgery (1, 3, 6, 12 months and yearly thereafter) in patients who underwent 113 
RYGB between June 2004 and May 2010, and had an outpatient visit between December 114 
2009 and May 2010 at Pitié-Salpêtrière University Hospital, Paris, France. 115 
Results:  The cohort included 143 patients (78% female, mean age 42.9 years, mean BMI 116 
48.6 kg/m²). Total prescription costs were significantly lower (-32%, p<0.001) one year after 117 
RYGB compared with preoperative costs. However, the cost for medications to prevent 118 
RYGB side effects (in particular nutritional deficiencies) displayed a 36-fold increase in the 119 
first month post-surgery, but then decreased progressively over time. Importantly, the cost 120 
related to the treatment of the two most frequent obesity-related diseases significantly 121 
decreased one year after surgery. Indeed, prescription costs for treatment of type 2 diabetes 122 
(T2D) and obstructive sleep apnea (OAS) (namely CPAP therapy considered as the gold 123 
standard treatment) were reduced one year after surgery by 85% and by 63% (both p<0.001), 124 
respectively. We also observed a trend toward a decrease in the prescription costs of other 125 
obesity-related diseases, although it didn’t reach significance in our cohort.  126 
Conclusions: Considering medication to treat both obesity-related diseases and prevention of 127 
secondary effects of bariatric surgery, we observed that overall post-operative medication 128 
costs were significantly reduced one year after surgery, especially for T2D and OSA.   129 
Abstract words: 244 130 
Keywords: Medication cost – Prescriptions – Obesity – Comorbidities - Bariatric surgery – 131 
Roux-en-Y gastric bypass  132 
133 
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Introduction 134 
The prevalence of obesity has increased worldwide over the last decades [1], thereby also 135 
increasing the prevalence of obesity-related diseases (such as type 2 diabetes mellitus (T2D), 136 
dyslipidemia, hypertension, cardiovascular diseases (CVD), but also obstructive sleep apnea 137 
(OSA), asthma, joint arthritis, and depression) [2]. Therefore, obese individuals are prone to 138 
increased consumption of drugs compared to lean individuals [3]. 139 
Medical management of obesity has proven disappointing on both the amount of weight loss 140 
and its maintenance over time [4]. Therefore, the number of patients undergoing bariatric 141 
surgery such as Roux-en-Y gastric bypass (RYGB), which is indicated for the most severe 142 
form of obesity, has increased dramatically. Most importantly, it is currently the only efficient 143 
mean to achieve major and sustainable weight reduction [2,5]. Along with a significant 144 
reduction in all-cause mortality, RYGB improves several obesity-related diseases [6-10], 145 
leading to a decreased consumption of related treatments [11]. Indeed, medication used for 146 
T2D, hypertension and dyslipidemia decreased significantly as early as 1 year post-surgery 147 
(by 76%, 51% and 59%, respectively) [12]. This reduction continued significantly 3 years 148 
post-surgery, in particular for T2D, dyslipidemia and CVD [11]. Finally, comparing obese 149 
patients post-surgery to an obese matched control group, the SOS study, demonstrated a 150 
significant reduction in the cost of drugs for obesity-related diseases after 7 years, which 151 
remained significantly lower during 20 years of follow-up [13].  152 
Although beneficial regarding mortality and obesity-related comorbidities, RYGB induces 153 
potential risks such as nutritional deficiencies and short term surgical complications such as 154 
venous thrombosis, anastomosis ulceration and gallstones [16-18].  155 
Both can be prevented by specific drug prescriptions such as daily vitamin and mineral 156 
substitution [14,15], hence inducing substantial costs. Few studies (if any) have yet addressed 157 
the overall treatment cost evolution after surgery taking into account not only treatment of 158 
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obesity-related diseases but also surgery side effects’ prevention. As it remains unclear to 159 
what extent RYGB may be cost-saving in terms of overall drug consumption, we aimed to 160 
examine the evolution of medication use and associated costs in RYGB patients.  161 
 162 
Methods and procedures 163 
Study design and data collection 164 
We took advantage of an ongoing clinical research protocol (approved by the Ethics 165 
Committee of Hôtel-Dieu Hospital) including all of our bariatric surgery patients followed at 166 
the Nutrition Department of Pitié-Salpêtrière hospital Paris, France. All subjects gave written 167 
informed consent. Only those who underwent RYGB were included. Bariatric surgery was 168 
decided in agreement with international clinical practice guidelines [19]. For the purpose of 169 
the study, patients who had undergone a previous bariatric surgery, as well as those who 170 
didn’t attend postoperative follow-up, were excluded.  171 
We first retrospectively included all patients who had undergone RYGB from June 2004 to 172 
November 2009, and for whom clinical data (age, sex, BMI) were available in our database 173 
both before (baseline) and 1, 3, 6 months (M) and yearly (Y) after surgery, until 4 years post-174 
RYGB, and who had a follow-up visit. We also prospectively included patients who came for 175 
a RYGB preoperative examination between December 2009 and May 2010. Data were 176 
collected from patient’s medical records and verified with the patient at the inclusion visit. 177 
Entire obesity-related diseases history and complete list of drugs and medical devices 178 
prescribed at each examination (including Continuous Positive Airway Pressure (CPAP), 179 
considered as the gold standard treatment of OSA) [20] was retrieved. The dosing regimen for 180 
each drug was also collected. 181 
Data analysis 182 
We tabulated drugs taken by each patient at each follow-up time point, including cost per 183 
month (in euros). The cost for each medication or medical device was obtained from the 184 
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official current price list (http://www.theriaque.org and www.ameli.fr) and when appropriate, 185 
generic drug costs for the largest package available, were used. Treatments were divided into 186 
curative use (further grouped according to the different obesity-related diseases they were 187 
used for (including CPAP treatment)), or preventive use (those to prevent surgery-related 188 
complications or potential nutritional deficiencies). The different categories of obesity-related 189 
diseases were defined upon medication use and thorough checking of the adequacy with each 190 
patient’s medical history. Patients with T2D were defined as those on oral anti-diabetic 191 
therapy and/or insulin and/or GLP-1 analogue. OSA included patients on CPAP treatment. 192 
CVD comprised antihypertensive drugs and/or antiplatelet agents and included secondary 193 
CVD prevention drugs. Dyslipidemia included patients treated with statin or fibrates. Psycho- 194 
and neurological disorders comprised patients who were on antidepressant therapy and those 195 
with anti-epileptic treatment. Lastly, a category called “other” included patients using pain 196 
killers, drugs used for asthma, hyperuricemia, skin complications, urinary incontinence or 197 
gastrointestinal problems. 198 
We used the Anatomical Therapeutic Chemical classification system (ATC-system), which 199 
categories drugs into different classes according to their therapeutic and chemical 200 
characteristics, at the first level, except for drugs used in metabolic disorders, which were 201 
classified at level 2 of the ATC-system (http://www.whocc.no/). Prevention treatment at our 202 
center has previously been described [13] and includes 2 weeks before surgery: vitamin D 203 
(once 4x100000IU), vitamin B1 (250mg/day), vitamin B12 (250µg/day) and esomeprazole 204 
(40mg/day). Esomeprazole dosing is maintained during 6 months post-surgery to prevent 205 
anastomosis ulcerations. Enoxaparine (4000IU 1inj/day) is prescribed for 3 weeks post-206 
surgery to prevent venous thrombosis. Fifteen days post-RYGB, vitamin and mineral 207 
supplements including Azinc optimal® (2x/day), iron (2x80mg/day), vitamin D (800IU/day) 208 
and calcium (1000mg/day) are started and continued on the long term. Ursodeoxycholic acid 209 
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is introduced 2 weeks post-surgery (only for patients with no previous history of 210 
cholecystectomy) and continued for 3 months to prevent gallstone formation known to be 211 
associated with major and rapid weight loss [16-19]. Besides this standard protocol, additional 212 
drugs and/or supplements to treat side effects related to surgery (vitamins, minerals and 213 
proteins, antiemetics,…) can be added on an individually-tailored basis. 214 
Statistical analysis 215 
Continuous variables are presented as mean±SD. The main outcome variables were the 216 
changes in the relative cost of each comorbidity treatment, calculated both in the whole cohort 217 
or considering only those patients affected with the comorbidity in question. Changes in (i) 218 
the total cost and (ii) the medication cost for both preventive and curative use were evaluated. 219 
Medication costs 1, 3, 6, 12, 24, 36 and 48 months after RYGB were compared with those at 220 
baseline. Two-way ANOVA and Chi-² tests were used. Statistical significance was set at p < 221 
0.05. 222 
Results 223 
We included 143 patients whose characteristics are displayed in Table 1. BMI gradually 224 
decreased during the first year post-RYGB and then stabilized up to four years (48.6±9 kg/m² 225 
vs. 33.2±8 kg/m²) (Figure 1) (ie: mean weight loss 33±18 kg). 226 
When compared to baseline values, we observed a significant 32% reduction in the total 227 
prescription costs one year post-surgery (p<0.01) (Figure 2). Curative medications and 228 
medical device cost significantly decreased as early as one month post-surgery and onwards 229 
(Figure 3). The most significant reduction in the mean prescription cost concerned T2D and 230 
OSA treatments (Table 2). Indeed, 34% of patients were treated for T2D at baseline, which 231 
was reduced respectively to 16%, 11%, 9% and 0%, after 3 months, 1, 2 and 4 years after 232 
RYGB. Likewise, T2D treatment cost decreased by 65% (p<0.01) at 1 month, and further 233 
over time to reach 0€ four years post-RYGB (Table 3). 234 
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OSA mean treatment cost decreased significantly as early as 3 months post-surgery and 235 
onwards to reach its lowest cost (12.86€/month) at three years (ie: 89% reduction vs. 236 
baseline). By contrast, drugs for CVD and dyslipidemia’s cost decreased more weakly (-237 
51.5% and -81%, respectively), only reaching significance one and two years post-RYGB. 238 
We observed no significant change regarding other obesity-related disease prescriptions.  239 
As expected, preventive treatment’s prescription just before the surgery induced a 36 fold 240 
increase in the cost one month post-surgery, compared with baseline. Although this cost 241 
decreased over time, but it remained significantly higher than baseline values, even after four 242 
years. 243 
Discussion  244 
This study aimed to investigate the overall medication costs after RYGB. We focused both on 245 
the costs of the different obesity-related diseases treatments, and those of treatments 246 
prescribed to prevent surgery-related complications, and observed a significant reduction in 247 
the global medication cost one year post-surgery and onwards, compared with baseline. This 248 
major post-surgery cost reduction was mainly explained by the acute decrease in T2D and 249 
OSA treatment prescriptions.  250 
The marked reduction in T2D medication use observed in our study, resulted in an 85 fold 251 
decrease in medication cost one year post-RYGB among the patients with diabetes, which is 252 
in line with previous pharmaco-economic studies. Segal et al [12] evaluated medication use in 253 
6,235 patients undergoing bariatric surgery and demonstrated 76% reduction in T2D 254 
medication use one year post-surgery that persisted up to four years [22].  A significant 255 
reduction in oral anti-diabetic agents and insulin therapy (80% and 79%) four years post-256 
RYGB was also observed in another study, including 191 diabetic patients [23].  Although 257 
our cohort was of a smaller size, the reduction of T2D treatment is in line with a significant 258 
improvement or normalization of both HBA1c and fasting glycemia during follow-up. 259 
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Literature entails that RYGB enables (i) a 57.5% T2D remission [24] according to the 260 
definition [25], (ii) an 84% improvement in T2D status [26], and (iii) a reduction in the 261 
occurrence of T2D [27]. We herein demonstrate a significant cost reduction as soon as one 262 
month post-RYGB, in agreement with the rapid improvement of diabetes post-surgery which 263 
involves multiple mechanisms [28-30], some unrelated to weight loss [23,28,31].  264 
OSA occurred in 33% of our patients at baseline. We observed a 63% reduction in the cost of 265 
CPAP one year post-RYGB, in line with previous studies [2,32-35]. Likewise, we confirmed 266 
the possibility to stop CPAP upon clinical examination and polysomnography. In contrast 267 
with T2D, OSA improvement only becomes apparent when substantial reduction in BMI 268 
occurs, suggesting the importance of maintained weight loss. Yet, as acknowledged by studies 269 
comparing the effects of surgical versus diet-induced weight loss [36], the improvement of 270 
OSA involves numerous mechanisms other than weight loss [37].  271 
Bariatric surgery reduces all-cause mortality, particularly death from CVD [5,21,38] and 272 
improves CVD risk factors [10]. We herein confirm the decrease in medication cost for 273 
dyslipidemia and CVD, reaching significance one and two years post-RYGB. However, these 274 
reductions were not significantly sustained on the longer term, although our patients didn’t 275 
regain weight over the four years follow-up (Figure 1). Previous reports showed that although 276 
51% and 59% of the patients could stop their hypertension or dyslipidemia medications soon 277 
post-surgery [39,40], the incidence of both diseases tends to increase again on the longer term 278 
(two and ten years) [5]. The fact that in our study drugs that were used for secondary 279 
prevention of cardiovascular events were pooled with drugs for hypertension and CVD could 280 
be another reason for the observation that reductions in drug costs for CVD did not sustain 281 
over time. Secondary prevention treatment is expected not to be discontinued, even if clinical 282 
or biological parameters improve.  283 
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By contrast, we did not observe a significant decrease in psycho-neurological treatment costs, 284 
in line with previous reports [44]. Indeed no significant change in the prevalence of 285 
antidepressant prescription was observed in a retrospective study including 439 patients 286 
before and post-RYGB [44]. Likewise, we recently demonstrated that the physical, but not the 287 
mental component of quality of life significantly improved one year after surgery [46]. 288 
While medication costs for curative use decreased, preventive medication costs increased 289 
immediately post-surgery. This can be explained by the choice of prevention regimen in our 290 
department [15]. Although the cost for preventive medication decreased over time, daily 291 
minerals and vitamins should never be discontinued as the prevention of nutrient deficiencies 292 
is lifelong [15]. 293 
 294 
Overall, the strength of our study lies in the fact that the evolution of treatment costs for 295 
obesity-related diseases was confronted with clinical examination and biological parameters 296 
obtained at each follow-up time point. This highlights the need for frequent medical follow-up 297 
enabling healthcare professionals to adapt the treatment to patients’ needs in order to avoid 298 
side effects, such as hypoglycemia with antidiabetic drugs. Furthermore, these patients should 299 
receive sufficient information about their medication use, and need frequent adaptation of the 300 
medication scheme after surgery to provide correct adherence.  We deliberately chose to limit 301 
our analysis on the impact of RYGB only, since different bariatric surgery techniques induce 302 
different results in terms of obesity-related diseases improvement or remission, thus 303 
impacting on drug associated costs.  304 
However, our study presents some limitations. The medication classification in preventive 305 
and curative use, and the different comorbidities, is rather arbitrary. Besides, the recruitment 306 
of patients in a university hospital reflects the most severe obese patients with worse 307 
conditions which might reinforce the beneficial cost’s reduction we herein observe. To 308 
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generalize our findings, our results need to be verified in a more general population of 309 
candidates to RYBG to validate whether they still hold true.  310 
Finally, we decided to focus on treatment costs and didn’t address other costs related to 311 
surgery follow-up, such as hospital days and non-primary care visits, thus we cannot conclude 312 
on the total health care costs. Some recent studies have however addressed this issue. The 313 
SOS study demonstrated that hospital days and visits were significantly reduced from 7 years 314 
and onwards after surgery when comparing surgery to non-surgery obese patients [13]. By 315 
contrast, Weiner et al failed to observe any difference in overall health care costs between 316 
surgery patients and a matched obese group [47]. Of note, in those two studies, multiple 317 
bariatric surgeries were assessed including techniques that are known to induce surgical 318 
reoperations such as lapband and vertical gastroplasty.  319 
 320 
Conclusion 321 
In this study we took into account medications prescribed for obesity-related diseases and for 322 
prevention of surgical and nutritional complications, thus reflecting everyday life post-RYGB. 323 
Our study shows that RYBG induces a significant reduction of total medication costs, as early 324 
as one year post RYGB, compared to baseline. Most importantly, the reduced medication cost 325 
was maintained over time several years post-RYGB and appears mainly to be due to the 326 
significant improvement of T2D and OSA. Hence, RYGB entails economic benefits by 327 
reducing the costs and need for medication and medical devices.  328 
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Figure legends 451 
 452 
Figure 1: Mean BMI ± SD before and after RYGB. On the x-axis the number of patients at 453 
each time point of the follow-up is represented.  (before surgery is referred as preop, 1M: 1 454 
month, 1Y: 1 year) 455 
Figure 2: Medication cost per month per person pre-and post-RYGB, subdivided in 456 
preventive and curative medication use; significant differences are shown in comparison with 457 
baseline costs. (before surgery is referred as preop, 1M: 1 month, 1Y: 1 year) 458 
Figure 3: Mean cost per patient per month for the different comorbidities, among the patients 459 
who suffer from the comorbidity. (before surgery is referred as preop, 1M: 1 month, 1Y: 1 460 
year) 461 
 462 
Table legends 463 
Table 1: Characteristics of the study cohort at baseline before RYGB surgery  464 
Table 2: Medication cost per month (at each time point post RYGB compared to baseline) 465 
Table 3: The different treatments for T2D before and after RYGB along the follow-up 466 
467 
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Table 1: Characteristics of the study cohort at baseline before RYGB surgery 468 
Patients characteristics  
Total 
Female, n (%) 
143 
112 (78.3%) 
Age (y), mean ± SD 
BMI (kg/m²), mean  ± SD                   
42.9  ± 12 
48.6 ± 8.8 
      Obesity related diseases n (%) 
Type 2 diabetes  
Obstructive sleep apnea 
Cardiovascular disease 
49 (34%) 
47 (33%) 
71 (50%) 
Dyslipidemia 38 (27%) 
Psycho- and neurological   disorders 44 (31%) 
 
 469 
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Table 2: Medication cost per month (at each time point post RYGB compared to baseline) 
Comorbidity 
 
Number of 
patients at 
baseline 
Average 
medication 
cost per 
month  at 
baseline (€) 
1 month 
post surgery 
(€) 
3 months 
post surgery 
(€) 
6 months 
post surgery  
(€) 
1 year  
post surgery 
(€) 
2 years  
post surgery 
(€) 
3 years  
post surgery 
(€) 
4 years  
post surgery 
(€) 
Type 2 Diabetes Patients with the 
comorbidity (n=49) 
81.0 
 
-52.6*** 
[-76.6;-28.7] 
-63.3*** 
[-87.3;-39.4] 
-66.0*** 
[-91.2;-40.8] 
-69.2*** 
[-94.7;-43.7] 
-67.4*** 
[-95.1;-39.6] 
-75.35*** 
[-107.6;-43.1] 
-81.0*** 
[-131.0;-31.1] 
All patients (n=143) 28.3 -20.2*** 
[-37.2;-3.2] 
-23.3*** 
[-40.1;-6.6] 
-24.2*** 
[-41.6;-6.9] 
-24.9*** 
[-43.0;-6.8] 
-24.48*** 
[-43.55;-5.4] 
-26.7*** 
[-49.3;-4.1] 
-28.3** 
[-57.2;0.55] 
Obstructive 
sleep apnea  
Patients with the 
comorbidity (n=47) 
115.7 
 
-14.1 
[-36.9;8.7] 
-21.5** 
[-44.3;1.3] 
-50.8*** 
[-73.9;-27.7] 
-72.7*** 
[-96.6;-48.8] 
-91.8*** 
[-117.2;-66.3] 
-102.8*** 
[-132.6;-73.1] 
-101.2*** 
[-142.1;-60.4] 
All patients (n=143) 35.6 0.6 
[-16.4;17.6] 
-1.8 
[-18.6;14.9] 
-10.7 
[-28.0;6.6] 
-19.2*** 
[-39.4;-1.1] 
-26.7*** 
[-45.8;-7.6] 
-30.8*** 
[-53.4;-8.2] 
-31.2*** 
[-60.0;-2.3] 
Cardiovascular 
diseases 
Patients with the 
comorbidity (n=71) 
33.2 
 
-3.9 
[-23.0;15.2] 
-9.4 
[-28.5-9.7] 
-7.4 
[-27.0;12.1] 
-13.6 
[-33.6;6.4] 
-17.1* 
[-37.7;3.4] 
-12.3 
[-36.4;11.8] 
-5.5 
[-37.6;26.6] 
All patients (n=143) 16.5 -2.7 
[-19.7;14.2] 
-5.9 
[-22.3;11.3] 
-4.0 
[-21.3;13.4] 
-6.2 
[-24.3;11.9] 
-7.4 
[-26.5;11.7] 
-4.3 
[-26.9;18.3] 
-1.6 
[-30.5;27.3] 
Dyslipidemia 
 
 
 
Patients with the 
comorbidity (n=38) 
27.1 
 
-5.6 
[-31.3;20.2] 
-14.7 
[-40.5;11.0] 
-17.9 
[-43.6;7.9] 
-22.0* 
[-49.1;5.1] 
-20.6 
[-49.5;8.3] 
-16.8 
[-49.2;15.6] 
-19.4 
[-66.1;27.4] 
All patients (n=143) 
 
7.2 
 
-1.8 
[-18.7;15.2] 
-4.0 
[-20.8;12.8] 
-4.5 
[-21.8;12.8] 
-5.8 
[-23.9;12.3] 
-5.4 
[-24.5;13.6] 
-4.0 
[-26.6;18.6] 
-5.2 
[-34.1;23.7] 
Psycho- and 
neurological 
disorders 
Patients with the 
comorbidity (n=44) 
All patients (n=143) 
18.0 
 
5.5 
-5.0 
[-28.5;18.6] 
-1.5 
[-18.4;15.5] 
-5.3 
[-28.8;18.3] 
-1.2 
[-18.0;15.6] 
-2.3 
[-26.8;22.2] 
0.5 
[-16.8;17.8] 
0.7 
[-25.0;26.5] 
1.6 
[-16.5;19.7] 
-2.0 
[-29.4;25.3] 
0.4 
[-18.7;19.5] 
-5.9 
[-36.9;25.2] 
-1.0 
[-23.6;21.6] 
7.7 
[-29.6;44.9] 
5.3 
[-23.6;34.2] 
Total curative 
cost 
All patients (n=143) 118.2 -42.8*** 
[-59.8;-25.9] 
-53.3*** 
[-70.1;-36.5] 
-54.7*** 
 [-72.0;-37.4] 
-64.9*** 
[-83.0;-46.8] 
-74.8*** 
[-93.9;-55.7] 
-75.0*** 
[-97.6;-52.4] 
-68.9*** 
[-97.8;-40.0] 
The mean difference between the medication cost per month (at each time post RYGB point compared to baseline) and the preoperative cost per 
month with the 95% confidence interval.  
The total number of patients was 143. 
*p<0.05; ** p<0.01; *** p<0.001 
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Table 3: The different treatments for T2D before and after RYGB along the follow-up 
 
Therapy Baseline  1M 3M 6M 1Y 2Y 3Y 4Y 
Monotherapy (n) 
(oral antidiabetic 
(OAD) 
15 
(31%) 
7 
(33%) 
7 
(37%) 
5 
(38.5%) 
3 
(30%) 
3 
(43%) 
2 
(67%) 
0 
Bitherapy  
(oral antidiabetic) 
10 
(20%) 
0 2 
(10%) 
2 
(15.5%) 
3 
(30%) 
2 
(28.5%) 
1 
(33%) 
0 
Tritherapy  
(oral antidiabetic) 
1 
(2%) 
0 0 0 0 0 0 0 
OAD + insulin 20 
(41%) 
4 
(19%) 
4 
(21%) 
3 
(23%) 
3 
(30%) 
2 
(28.5%) 
0 0 
Insulin only 3 
(6%) 
10  
(48%) 
6 
(32%) 
3 
(23%) 
1 
(10%) 
0 0 0 
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Figure 1: Mean BMI ± SD before and after RYGB. On the X axis is represented the number of patient 
at each time point of the follow-up. (before surgery is referred as preop, 1M: 1 month, 1Y : 1 year) 
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Figure 2: Medication cost per month per person pre-and post-RYGB, subdivided in preventive and 
curative medication use; significant differences are shown in comparison with baseline costs. (before 
surgery is referred as preop, 1M: 1 month, 1Y : 1 year), *: p<0.05; ***: p<0.001 
 
PREOP            1M  3M       6M                1Y                  2Y                 3Y       4Y 
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Figure 3: Mean cost per patient per month for the different comorbidities, among the patients who suffer from the comorbidity. (before surgery is referred 
as preop, 1M: 1 month, 1Y : 1 year) 
